Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.32 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.32 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.32 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.32 |
| ▸ | DUT | P33316 | 6/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5671911 | 0.93 | SLC28A1 (0.35) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL7206853 | 0.86 | DUT (0.32) | DUT | |
| SCHEMBL6318834 | 0.85 | DUT (0.33) | DUT | |
| SCHEMBL7209224 | 0.84 | SLC28A1 (0.33) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL4085513 | 0.82 | SLC28A1 (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL6756343 | 0.79 | RNASE1 (0.36) | — | |
| SCHEMBL8227198 | 0.78 | PYGM (0.37) | — | |
| SCHEMBL29834207 | 0.78 | SLC28A1 (0.35) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL7212072 | 0.78 | DUT (0.31) | DUT | |
| SCHEMBL7206858 | 0.76 | DUT (0.33) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772469-B2 | Synthetic double-stranded oligonucleotides for specific inhibition of gene expression | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2014-07-08 | — | — | US | disclosed |
| US-20030139585-A1 | Synthetic double-stranded oligonucleotides for specific inhibition of gene expression | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139585-A1 | Synthetic double-stranded oligonucleotides for specific inhibition of gene expression | DCLRE1B, RIOX2, SRRT | SLC28A1 1225/4885SLC28A2 881/4885SLC29A1 1431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.